Evidence map›Paper›PMID 41553857›Full record

ArticleCancer science2026

Development and Validation of a Urinary Exosomal miRNA Diagnostic Panel for Early Detection of Esophageal Cancer.

Tatsuro Murano, Hiroki Yamashita, Yuki Kano, Ken Takeuchi, Takayuki Amano, Takanobu Yoshimoto, Mayuko Otomo, Hisashi Fujiwara, Shin Namiki, Hiroki Yamaguchi and 5 more

Abstract readValidation Study
In one paragraph

Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tatsuro MuranoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.ORCID https://orcid.org/0000-0003-0423-2151
Hiroki YamashitaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.
Yuki KanoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.
Ken TakeuchiDepartment of Gastroenterology, IBD Center, Tsujinaka Hospital Kashiwanoha, Chiba, Japan.
Takayuki AmanoMedical Corporation Doyukai Kasuga Clinic, Tokyo, Japan.
Takanobu YoshimotoMedical Corporation Doyukai Kasuga Clinic, Tokyo, Japan.
Mayuko OtomoDepartment of Gastrointestinal Surgery, Institute of Science, Tokyo, Tokyo, Japan.
Hisashi FujiwaraDepartment of Gastrointestinal Surgery, Institute of Science, Tokyo, Tokyo, Japan.
Shin NamikiDepartment of Gastroenterology, Tokyo Metropolitan Tama Medical Hospital, Tokyo, Japan.
Hiroki YamaguchiCraif Inc, Aichi, Japan.
Yoriko AndoCraif Inc, Aichi, Japan.
Yumi NishiyamaCraif Inc, Aichi, Japan.
Mika MizunumaCraif Inc, Aichi, Japan.
Yuki IchikawaCraif Inc, Aichi, Japan.
Tomonori YanoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.ORCID https://orcid.org/0000-0002-8030-1449

Funding

JSPS KAKENHI 19K17417Medical Research and Development Program JP24he2302007
6 · The paper itself

Abstract

Esophageal squamous cell carcinoma (ESCC) remains a leading cause of cancer-related mortality, with early detection being challenging. Although endoscopic screening can aid in diagnosis, its invasiveness and cost limit widespread compliance. To address this, we developed and validated a non-invasive diagnostic panel based on urinary exosomal microRNAs (miRNAs) for early ESCC detection. Urine samples were prospectively collected from ESCC patients and healthy controls across five institutions, and exosomal miRNA profiles were obtained using small RNA sequencing. A diagnostic panel was constructed using machine learning with recursive feature elimination in a proof-of-concept (POC) cohort comprising 99 ESCC and 93 control samples, and its performance was evaluated by five-fold cross-validation. This panel was subsequently tested in a blinded validation cohort of 50 ESCC and 61 control samples. In the POC cohort, the multi-miRNA panel achieved an area under the curve (AUC) of 0.90. In the validation cohort, the AUC was 0.85 (95% CI: 0.77-0.92), with 84% sensitivity and 66% specificity. The panel showed high sensitivity across disease stages-100% for Stage 0, 91% for Stage I, and 73% for Stages II-IV-and its performance was not significantly affected by sex, body mass index, alcohol use, or smoking. Furthermore, in early-stage cases, the diagnostic score significantly declined after treatment (p = 0.026). These findings suggest that the urinary exosomal miRNA panel may offer a practical screening approach for the early detection of ESCC.

Indexed as

Biomarkers, TumorEarly Detection of CancerEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaExosomesMicroRNAsAgedFemaleHumansMaleMiddle AgedSensitivity and SpecificityBiomarkers, TumorMicroRNAsbiomarkeresophageal squamous cell carcinomaliquid biopsymicroRNAurine

Identifiers

PMID41553857
PMCPMC13045446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.